Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

Company Performance - Alto Neuroscience, Inc. (ANRO) has returned 168.3% year-to-date, significantly outperforming the Medical sector, which has gained about 5.4% on average [4] - The Zacks Consensus Estimate for ANRO's full-year earnings has increased by 1.9% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [3] - Alto Neuroscience, Inc. holds a Zacks Rank of 2 (Buy), suggesting strong potential for continued performance [3][6] Industry Context - Alto Neuroscience, Inc. is part of the Medical - Biomedical and Genetics industry, which includes 469 individual stocks and currently ranks 87 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has averaged a gain of 15% year-to-date, indicating that ANRO is performing better than its industry peers [6] - Editas Medicine (EDIT), another stock in the Medical sector, has also outperformed the sector with a year-to-date return of 100% [4][5]